Search

The albumin-bilirubin (ALBI) grade, stratified from the ALBI score, may have prognostic value in patients with hepatocellular carcinoma. We aim to evaluate the prognostic abilities of the ALBI score/grade among living-donor liver transplantation patients. We retrospectively collected data of 81 patients who underwent living-donor liver transplant at Kobe University Hospital between June 2000 and October 2018. The efficacy of the ALBI score/grade as a prognostic factor was assessed and compared with that of the well-established Model for End-Stage Liver Disease (MELD) score. Multivariate analysis indicated that recipient age (P =.003), donor age (P =.003), ALBI score ≥ −1.28 (P =.002), and ALBI grade III (P =.004) were independently associated with post-transplant survival. A high MELD score was not associated with post-transplant survival in univariate or multivariate analyses. Although there was no significant difference in the overall survival rate relative to recipient and donor age, ALBI score/grade was significantly associated with the 1- and 5-year survival rates (P =.023, P =.005). ALBI scores specifically detected fatal complications of post-transplant graft dysfunction (P =.031) and infection (P =.020). ALBI score/grade predicted patient survival more precisely than the MELD score did, suggesting that it is a more useful prognostic factor compared to the MELD score in living-donor liver transplantation cases. • An albumin-bilirubin score predicts recipient survival after living-donor transplantation. • An albumin-bilirubin score is more useful than Model for End-Stage Liver Disease score. • An albumin-bilirubin score of ≥ −1.28 is independently associated with worth survival. • A high albumin-bilirubin score predicts an incidence of infection and graft dysfunction. [ABSTRACT FROM AUTHOR]